New clinical study shows Nevisense potential for assessment of Skin Barrier and Atopic DermatitisApril 12, 2021
STOCKHOLM, SWEDEN, - April 12, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today the publication of a new clinical study supporting SciBase's strategy to develop multiple clinical applications for the Nevisense and Nevisense Go platforms.
SciBase publishes the Annual report for 2020April 9, 2021
SciBase hereby announces that the Annual report for 2020 is available at the Company's website www.scibase.com.
SciBase announces a Management team changeMarch 9, 2021
SciBase's head of product development, David Melin, has resigned from his position and has accepted a role at another company. The company is reviewing options for the role going forward.
"I would like to take the opportunity to thank David for his exceptional work at SciBase, and especially his work with our Nevisense hardware platforms. David has managed a very well-functioning development team, and I wish him all the best in his future role", says Simon Grant CEO SciBase.
For more information, please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Certified Advisor (CA):
Tel: +46 8 409 421 20
The information was submitted, through the agency of the contact person set out above, for publication at the time stated by SciBase's news distributor Cision upon publication of this press release.
About SciBase and Nevisense
SciBase AB is a Swedish medical technology company, headquartered in Stockholm that has developed and sells a unique point-of-care device for evaluation of skin disorders such as skin cancer and atopic dermatitis. Its first product, Nevisense, helps doctors to detect malignant melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and inflammation. SciBase was founded by Stig Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. Nevisense is based on a method called Electrical Impedance Spectroscopy (EIS), which uses the varying electrical properties of human tissue to categorize cellular structures and thereby detect malignancies and abnormalities. SciBase is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.
- Load more news...